ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

CRYO Cryo-Save

420.00
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Cryo-Save LSE:CRYO London Ordinary Share NL0009272137 ORD EUR0.10 (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 420.00 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Share Consolidation

08/10/2009 7:00am

UK Regulatory



 

TIDMCRYO 
 
RNS Number : 4183A 
Cryo-Save Group NV 
08 October 2009 
 

8 October 2009 
 
 
Cryo-Save Group NV 
 
 
Share Consolidation 
 
 
Cryo-Save Group N.V. (AIM: CRYO, "Cryo-Save" or "the Company"), Europe's leading 
stem cell bank, confirms that pursuant to the passing of the relevant 
resolutions at an EGM of the Company held on 5 October 2009, and as notified on 
that day, the proposed 5:1 share consolidation has this morning become 
effective. 
 
 
As result of the share consolidation the Company's authorised share capital now 
comprises 9,639,191 ordinary shares of EUR0.10 each; the associated depository 
interests for these ordinary shares will commence trading at 8:00am today under 
ISIN NL0009272137. 
 
 
 
 
+------------------------------------+---------------------------------+ 
| For further details:               |                                 | 
+------------------------------------+---------------------------------+ 
|                                    |                                 | 
+------------------------------------+---------------------------------+ 
| Cryo-Save Group                    | + 31 (0)575 548998              | 
+------------------------------------+---------------------------------+ 
| Marc Waeterschoot, Chief Executive |                                 | 
|                                    |                                 | 
+------------------------------------+---------------------------------+ 
| Arnoud van Tulder, Chief Financial |                                 | 
| Officer                            |                                 | 
+------------------------------------+---------------------------------+ 
|                                    |                                 | 
+------------------------------------+---------------------------------+ 
| Daniel Stewart & Company plc       | + 44 (0) 20 7776 6550           | 
+------------------------------------+---------------------------------+ 
| Simon Leathers                     |                                 | 
+------------------------------------+---------------------------------+ 
|                                    |                                 | 
+------------------------------------+---------------------------------+ 
| College Hill                       | + 44 (0) 20 7457 2020           | 
+------------------------------------+---------------------------------+ 
| Adrian Duffield/Rozi Morris        |                                 | 
+------------------------------------+---------------------------------+ 
 
 
About Cryo-Save 
 
 
With more than 115,000 samples saved, Cryo-Save is the leading stem cell bank in 
Europe and one of the fastest growing in the world. Driven by its international 
business strategy, Cryo-Save is now represented in 38 countries on three 
continents and has state-of-the-art processing facilities in Belgium, Germany, 
Dubai, India and France (under construction). 
 
 
Cryo-Save sets the highest quality standards in stem cell storage, as it aims to 
make an important contribution to conquer possible life-threatening diseases in 
the future. As a service to the public, Cryo-Save offers a Cost-free Family 
Donation Programme, free of charge, to families wishing to store their newborn's 
umbilical cord blood stem cells for a family member diagnosed with a 
life-threatening disease treatable by stem cells. The company is committed to 
further improve stem cell cryopreservation techniques, by participating in 
European Commission funded projects, in Universities and Hospitals. 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 CARZGMGGKNKGLZM 
 

1 Year Cryo-Save Chart

1 Year Cryo-Save Chart

1 Month Cryo-Save Chart

1 Month Cryo-Save Chart